Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3A | P49840 | 18/20 | 0.42 |
| ▸ | SRC | P12931 | 6/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 7/20 | 0.40 |
| ▸ | SYK | P43405 | 5/20 | 0.40 |
| ▸ | MAPK12 | P53778 | 4/20 | 0.40 |
| ▸ | HCK | P08631 | 1/20 | 0.40 |
| ▸ | GSK3B | P49841 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6584730 | 0.86 | GSK3A (0.43) | GSK3ASRCMAPK14SYKMAPK12 | |
| SCHEMBL6583148 | 0.84 | GSK3A (0.42) | GSK3ASRCMAPK14SYKMAPK12 | |
| SCHEMBL6583633 | 0.83 | GSK3A (0.45) | GSK3ASRCMAPK14SYKMAPK12 | |
| SCHEMBL6585714 | 0.83 | KDR (0.44) | GSK3ASRCMAPK14SYKMAPK12 | |
| SCHEMBL6585819 | 0.83 | KDR (0.40) | GSK3ASRCMAPK14SYKMAPK12 | |
| SCHEMBL6587587 | 0.83 | SYK (0.44) | GSK3ASRCMAPK14SYKMAPK12 | |
| SCHEMBL6583630 | 0.80 | MAPK14 (0.40) | GSK3ASRCMAPK14SYKMAPK12 | |
| SCHEMBL6598212 | 0.78 | KDR (0.40) | GSK3ASRCMAPK14SYKMAPK12 | |
| SCHEMBL6583664 | 0.78 | KDR (0.40) | GSK3ASRCMAPK14SYKMAPK12 | |
| SCHEMBL6810815 | 0.77 | KDR (0.42) | GSK3AMAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030100608-A1 | 1,4-disubstituted benzo-fused cycloalkyl urea compounds | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2003-05-29 | — | — | US | claimed |
| EP-1414810-A2 | 1,4-DISUBSTITUTED BENZO-FUSED CYCLOALKYL UREA COMPOUNDS | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2004-05-06 | — | — | EP | disclosed |
| US-6720321-B2 | REACTING THE ALDEHYDE WITH CARBETHOXYMETHYLENE TRIPHENYLYPHOSPHORANE TO FORM UNSATURATED ESTER, REACTING ESTER WITH DIAZOMETHANE IN PRESENCE OF PALLADIUM ACETATE TO FORM CYCLOPROPANE CABROXYLIC ESTER, HYDROLYSIS TO FORM ACID | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2004-04-13 | — | — | US | disclosed |
| WO-2002098869-A2 | 1,4-DISUBSTITUTED BENZO-FUSED CYCLOALKYL UREA COMPOUNDS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2002-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030100608-A1 | 1,4-disubstituted benzo-fused cycloalkyl urea compounds | MPO, NFKBIA, YBX1 | GSK3A 4608/4885SRC 3689/4885MAPK14 3283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.